Antibacterials
- PDF / 169,923 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 71 Downloads / 158 Views
1 S
Death: 12 case reports In a retrospective study involving 489 patients who were admitted to a university hospital in Brazil between January 2013 and December 2017 for carbapenem-resistant Acinetobacter baumannii infection, 12 patients aged 42–89 years [sexes not stated] were described, who died after receiving antibacterial treatment with ertapenem, imipenem, meropenem polymixin-B [polymyxin-B] or tigecycline [dosages, routes and duration of treatment tor reaction onsets not stated, immediate causes of death not stated]. The patients were hospitalised due to head trauma, pneumonia, pleural effusion, chronic renal insufficiency, brain cancer, urinary insufficiency, femur fracture, stroke or hydrocephalus. Prior antibacterial therapies (administered for a minimum of 2 days within 30 days of current hospitalisation) of the patients included ertapenem, imipenem, meropenem or polymixin-B along with various other medications. Subsequently during hospitalisation, all the patients developed carbapenem-resistant Acinetobacter baumannii infection (hospital acquired infection). Therefore, the patients started receiving treatment with tigecycline along with polymixin-B, ampicillin/sulbactam or teicoplanin (definitive therapy). However, all the patients died within 30 days after the development of infection (total days of hospitalisation 20–108 days). The risk factors for 30 day mortality included prior antibacterial therapies with ertapenem, imipenem, meropenem or polymixin-B, or treatment with tigecycline during hospitalisation along with long hospital stay, invasive procedures and comorbidities. Rossi I, et al. Incidence of infections caused by carbapenem-resistant Acinetobacter baumannii. American Journal of Infection Control 47: 1431-1435, No. 12, Dec 2019. 803500234 Available from: URL: http://doi.org/10.1016/j.ajic.2019.07.009
0114-9954/20/1821-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 12 Sep 2020 No. 1821
Data Loading...
